Four things to know:
1. Pfizer first invested in Biohaven last November, according to ABC News. The company will buy all remaining shares at $148.50 per share in cash.
2. Biohaven makes rimegepant, an FDA-approved drug used to treat and prevent migraines.
3. The acquisition comes as Pfizer seeks to increase its portfolio before several of its key drugs lose patent exclusivity over the next decade, according to ABC News.
4. The deal represents the largest Pfizer has made since acquiring Medivation for $14 billion in 2016.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.